Multiple Sclerosis & Demyelinating Disease

📋 Key Information Summary

📋

Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disease of the central nervous system, affecting approximately 33,000 Australians, with prevalence highest in temperate southern states (Tasmania, Victoria).
Clinically isolated syndrome (CIS) is a first clinical episode suggestive of demyelination; MRI lesions fulfilling the 2017 McDonald criteria allow dissemination in space and time to be satisfied at presentation, enabling earlier diagnosis.
CSF oligoclonal bands are detected in ≥90% of MS patients and can substitute for dissemination in time when MRI criteria are not fully met (2017 McDonald revision).
Diagnosis requires exclusion of MS mimics including neuromyelitis optica spectrum disorder (NMOSD), MOG antibody disease (MOGAD), systemic lupus erythematosus, sarcoidosis, and vitamin B12 deficiency.
All suspected MS should be referred to neurology; urgent referral (within 2 weeks) is indicated for acute transverse myelitis, optic neuritis with severe visual loss, or suspected tumefactive MS.
Disease-modifying therapies (DMTs) are PBS-listed and include injectable (interferon-β, glatiramer), oral (dimethyl fumarate, teriflunomide, fingolimod, siponimod, cladribine), and high-efficacy infused therapies (natalizumab, ocrelizumab, alemtuzumab).
Symptom management in primary care covers spasticity (baclofen, gabapentin), fatigue (exercise, amantadine off-label), bladder dysfunction (oxybutynin, intermittent self-catheterisation), neuropathic pain (pregabalin, amitriptyline), and mood (SSRIs, psychological support).
Vaccination should be completed before initiating immunosuppressive DMTs; live vaccines are contraindicated during treatment with most DMTs.
Pregnancy planning is essential—teriflunomide and fingolimod are teratogenic and require washout; natalizumab and ocrelizumab have specific pre-conception timing guidelines.
Regular monitoring includes MRI (annual for most DMTs), lymphocyte counts, liver function, JC virus antibody status (natalizumab), and screening for opportunistic infections.
Aboriginal and Torres Strait Islander Australians face delayed diagnosis due to geographic barriers, reduced specialist access, and culturally inappropriate service delivery, requiring tailored outreach and telehealth solutions.
Mental health screening with PHQ-9 and GAD-7 should occur at every clinic visit; depression affects up to 50% of people with MS and significantly impacts treatment adherence and quality of life.

Introduction & Australian Epidemiology

Multiple sclerosis is a chronic, immune-mediated demyelinating disease of the central nervous system characterised by inflammatory lesions, demyelination, axonal injury, and gliosis in the brain, spinal cord, and optic nerves. It is the most common acquired disabling neurological disease in young adults, typically presenting between ages 20–40 years, with a female-to-male ratio of approximately 3:1.

Australia has one of the highest prevalence rates of MS globally. The 2024 AIHW report estimates approximately 33,300 Australians live with MS, equating to a prevalence of around 130 per 100,000 population. Prevalence demonstrates a clear latitude gradient, with Tasmania (~290 per 100,000) and Victoria having the highest rates, consistent with the well-established relationship between distance from the equator, reduced ultraviolet B exposure, lower vitamin D levels, and MS risk.

🌏

Australian burden: MS is the leading cause of non-traumatic neurological disability in young Australians. The estimated economic cost exceeds $1.75 billion annually (direct and indirect costs). The average age of diagnosis is 30 years, and median time from symptom onset to diagnosis is approximately 1–2 years (MS Australia, 2023).

Disease Subtypes

Subtype	Frequency	Characteristics
Relapsing-remitting MS (RRMS)	~85% at onset	Discrete relapses with full or partial recovery; stable between attacks
Secondary progressive MS (SPMS)	~50% of RRMS after 15–20 years	Gradual neurological deterioration after initial RRMS course; may have superimposed relapses (active SPMS)
Primary progressive MS (PPMS)	~10–15%	Steady decline from onset without discrete relapses; more common in men, older age at onset (~40–50 years)
Clinically Isolated Syndrome (CIS)	Precedes MS diagnosis	First clinical episode; may or may not convert to MS

Risk Factors

Genetic: HLA-DRB1*15:01 (strongest single risk factor, OR ~3); first-degree relative risk 2–4% (20–40× general population)
Environmental: Low vitamin D, Epstein-Barr virus seropositivity (near-universal but higher titres associated), smoking, adolescent obesity
Protective: High UV exposure, higher vitamin D levels, EBV vaccination (theoretical)

Clinically Isolated Syndrome

Clinically isolated syndrome (CIS) is defined as a first monophasic clinical episode with features suggestive of central nervous system demyelination, lasting at least 24 hours, in the absence of fever or infection. It is the earliest clinical presentation that may ultimately lead to a diagnosis of relapsing-remitting multiple sclerosis.

Typical Presentations

Common

Optic Neuritis

Unilateral painful vision loss over days; relative afferent pupillary defect; colour desaturation; typically improves over 4–12 weeks. Most common CIS in Australian cohorts.

Setting: Ophthalmology assessment + neurology referral

Common

Sensory/Motor Brainstem Syndrome

Internuclear ophthalmoplegia, diplopia, vertigo, facial numbness, trigeminal neuralgia (young patient), dysarthria, or facial palsy.

Setting: ED assessment → urgent neurology

Serious

Partial Transverse Myelitis

Sensory level, paraparesis, Lhermitte's sign, bowel/bladder dysfunction; typically incomplete cord syndrome (Brown-Séquard pattern). If complete transverse myelitis — investigate for NMOSD/MOGAD.

Setting: Emergency admission → MRI spine → neurology

⚠️

Red flags requiring urgent neurology referral: Complete transverse myelitis (sensory level with motor + sphincter involvement), severe bilateral visual loss, brainstem syndrome with respiratory compromise, progressive myelopathy, or any presentation with atypical features (seizures, encephalopathy, fever). These may indicate NMOSD, MOGAD, or other emergencies requiring distinct management pathways.

MRI Criteria in CIS

MRI brain and full spinal cord (with gadolinium) is the most important investigation in CIS. The presence of T2/FLAIR white matter lesions in typical periventricular, juxtacortical, infratentorial, or spinal cord distributions allows assessment of dissemination in space (DIS) per the 2017 McDonald criteria.

MRI Finding	Prognostic Significance	Conversion Risk
≥1 T2 lesion in ≥2 typical MS locations (periventricular, cortical/juxtacortical, infratentorial, spinal cord)	Meets DIS; high conversion risk	~70–80% at 15 years
Gadolinium-enhancing + non-enhancing lesion simultaneously	Satisfies DIT without waiting for second clinical attack	~80–90% at 15 years
Normal MRI brain	Lower but not negligible risk	~20–25% at 15 years
Spinal cord lesions at presentation	Independent predictor of MS conversion	Increases conversion risk by ~2×

CSF Oligoclonal Bands

Cerebrospinal fluid analysis for oligoclonal bands (OCBs) using isoelectric focusing is a key supporting investigation in CIS. OCBs present in CSF but absent from matched serum are found in ≥90% of MS patients and represent intrathecal immunoglobulin synthesis.

In the 2017 McDonald criteria, CSF OCBs can substitute for dissemination in time (DIT) when MRI DIT criteria are not met — this is a critical change allowing earlier diagnosis
OCBs are not specific to MS — also found in NMOSD (~30%), MOGAD (~15–20%), neurosarcoidosis, CNS infections, and lymphoma
CSF cell count, protein, glucose, and cytology should also be analysed to exclude alternative diagnoses
MBS item 65091 (lumbar puncture) and 73841 (CSF analysis including oligoclonal bands) are available at most Australian public hospitals; OCB testing requires paired serum and CSF samples

Risk of Conversion to MS

📊

Conversion rates (Australian longitudinal data, OPTIC study): Approximately 45–50% of CIS patients will convert to clinically definite MS within 2 years; 70–80% within 15 years if presenting MRI shows ≥1 lesion. Among those with a normal MRI at CIS, conversion rates are approximately 10–25% over 15 years. Early high-efficacy DMT initiation in high-risk CIS significantly reduces long-term disability accumulation (OVITO study, 2023).

Early Disease-Modifying Therapy in CIS

Patients with CIS and high-risk features (≥1 T2 lesion on MRI, positive CSF OCBs) should be considered for early DMT initiation, as this reduces conversion to MS and long-term disability accumulation. Several DMTs have PBS authority approval for use in CIS with high-risk MRI features in Australia.

💊

Interferon β-1a

Avonex® · Rebif® · Interferon beta-1a biosimilars · Immunomodulator

Adult dose Avonex: 30 µg IM once weekly; Rebif: 44 µg SC three times weekly

Paediatric dose Not indicated for CIS <18 years (off-label only)

Route / Frequency IM (Avonex) or SC (Rebif); ongoing

Renal adjustment No adjustment required

Key monitoring FBC, LFTs at baseline, 1, 3, 6 months then 6-monthly; thyroid function annually

PBS status ✔ PBS Authority Required — Relapsing-remitting MS or CIS with high-risk MRI

💊

Glatiramer acetate

Copaxone® · Glatopa® · Immunomodulator

Adult dose 20 mg SC daily or 40 mg SC three times weekly

Paediatric dose Not routinely used <18 years

Key monitoring Baseline LFTs; no routine blood monitoring required; injection site reactions common

PBS status ✔ PBS Authority Required

💊

Dimethyl fumarate

Tecfidera® · Immunomodulator

Adult dose 120 mg PO BD for 7 days, then 240 mg PO BD

Key monitoring FBC with differential lymphocyte count at baseline, 6 months, 12 months, then 6-monthly; LFTs

PBS status ✔ PBS Authority Required

Diagnosis of Multiple Sclerosis

The diagnosis of MS requires objective evidence of demyelination disseminated in both space (DIS — multiple areas of the CNS affected) and time (DIT — lesions occurring at different time points). The 2017 McDonald criteria are the internationally accepted diagnostic framework, with specific modifications applicable to Australian practice.

2017 McDonald Diagnostic Criteria — Relapsing MS

Clinical Presentation	Additional Data Needed for Diagnosis
≥2 clinical attacks + objective clinical evidence of ≥2 lesions	None further required — clinical criteria sufficient
≥2 attacks + objective evidence of 1 lesion	DIS by MRI (≥1 T2 lesion in ≥2 of 4 typical locations: periventricular, cortical/juxtacortical, infratentorial, spinal cord) OR await second clinical attack in different CNS location
1 clinical attack + objective evidence of ≥2 lesions	DIT by MRI (simultaneous gadolinium-enhancing and non-enhancing lesions OR new T2/contrast-enhancing lesion on follow-up MRI) OR CSF OCBs OR await second clinical attack
1 clinical attack + 1 lesion (clinically isolated syndrome)	DIS by MRI + DIT by MRI OR CSF OCBs + DIT by MRI OR await second clinical attack
Insidious neurological progression suggestive of MS (PPMS)	≥1 year of disability progression (retrospective or prospective) PLUS 2 of 3: ≥1 T2 lesion in periventricular, cortical/juxtacortical, or infratentorial regions; ≥2 T2 lesions in spinal cord; CSF OCBs

2017 McDonald Criteria — Key Revisions Relevant to Australian Practice

Symptomatic lesions can now be counted toward DIS and DIT (previously excluded)
Cortical lesions now count toward DIS alongside juxtacortical lesions
CSF OCBs can substitute for DIT in all clinical presentations
The criteria may be applied to diverse populations but were primarily validated in predominantly Caucasian cohorts; caution in Asian and Afro-Caribbean populations where NMOSD prevalence is higher

Differential Diagnosis — Must Not Be Missed

🚨

Critical MS mimics: Misdiagnosis of MS remains common (up to 5–10% in some series). The following conditions must be actively excluded before confirming MS, as misdiagnosis leads to inappropriate immunosuppression with potentially serious consequences.

Condition	Distinguishing Features	Key Investigations
NMOSD (AQP4-IgG)	Severe optic neuritis, complete transverse myelitis (≥3 vertebral segments), area postrema syndrome (intractable nausea/vomiting), bilateral or simultaneous CNS events	AQP4-IgG (serum cell-based assay); MRI long cord lesion ≥3 segments; brain MRI may be normal
MOG antibody disease (MOGAD)	Bilateral optic neuritis, ADEM-like presentation (especially children), conus/cauda equina lesions, relapsing course possible	MOG-IgG (live cell-based assay); MRI optic nerve enhancement; may have negative OCBs
Systemic lupus erythematosus / Sjögren's syndrome	Multisystem features, rash, arthritis, serositis; CNS vasculitis can mimic MS lesions	ANA, anti-dsDNA, ENA, complement levels, anti-Ro/anti-La
Neurosarcoidosis	Leptomeningeal enhancement, cranial neuropathies, hypothalamic/pituitary involvement, systemic features	ACE, chest CT, CSF, biopsy; leptomeningeal biopsy if accessible
CNS lymphoma	Solitary or few ring-enhancing lesions, mass effect, rapid progression; immunocompromised patients	MR spectroscopy, CSF cytology, stereotactic biopsy
Vitamin B12 deficiency	Subacute combined degeneration; posterior column involvement; peripheral neuropathy; macrocytic anaemia	Serum B12, methylmalonic acid, homocysteine
CNS infections (HIV, HTLV-1, Lyme, PML)	Geographical risk factors, immunosuppression, atypical MRI features	HIV serology, HTLV-1/2, JC virus (CSF PCR if PML suspected)

Timing of Referral to Neurology

1

Urgent (within 2 weeks)

Acute transverse myelitis with motor deficit, optic neuritis with severe visual loss, suspected tumefactive MS, brainstem syndrome with neurological compromise. Refer directly to ED/neurology registrar.

2

Soon (within 4–6 weeks)

First presentation suggestive of demyelination (optic neuritis with good recovery, sensory CIS, Lhermitte's sign), MRI incidentally showing periventricular white matter lesions suggestive of demyelination.

3

Routine (within 3 months)

Non-specific white matter lesions on MRI requiring specialist interpretation; known MS with new or worsening symptoms; discussion regarding DMT initiation or change.

Diagnostic Investigations

Essential

MRI Brain with Gadolinium (MBS 63520)

First-line investigation. Look for periventricular, juxtacortical, infratentorial, and spinal cord T2/FLAIR lesions. Gadolinium enhancement indicates active inflammation (within ~6 weeks). Use 3T where available for improved sensitivity. Required in all suspected MS.

Essential

MRI Whole Spine with Gadolinium (MBS 63553)

Mandatory in CIS and PPMS evaluation. Short-tau inversion recovery (STIR) sequences improve lesion detection. Exclude long cord lesion (>3 segments) suggesting NMOSD/MOGAD.

Available

Lumbar Puncture with OCBs (MBS 65091, 73841)

CSF oligoclonal bands (paired with serum). Supports diagnosis when MRI criteria incomplete. Also assesses cell count, protein, glucose, cytology to exclude mimics. Available at most public hospital pathology departments.

Available

Visual Evoked Potentials (VEP) (MBS 11005)

Prolonged P100 latency indicates optic nerve demyelination. Supportive when MRI or CSF is inconclusive. Less commonly required since 2017 McDonald revisions.

Referral

AQP4-IgG and MOG-IgG Antibodies

Serum cell-based assays to exclude NMOSD and MOGAD. Must be sent in all atypical presentations (complete myelitis, bilateral optic neuritis, area postrema syndrome, severe relapse). Available at major reference laboratories (e.g., Royal Prince Alfred Hospital, Melbourne Health).

Available

Serum Vitamin B12, Folate, TSH, ANA, Syphilis, HIV

Baseline screening to exclude common MS mimics and comorbidities. Routine in all patients with first demyelinating event.

Symptom Management

Symptom management is a core component of MS care and a primary care responsibility in coordination with neurology, allied health, and specialist nursing. Up to 90% of people with MS experience bothersome symptoms that significantly affect quality of life, employment, and relationships. Management should follow a multidisciplinary, patient-centred approach.

Spasticity

Spasticity affects approximately 60–80% of people with MS and may manifest as muscle stiffness, spasms (tonic, clonic, or flexor), pain, and functional impairment. Assessment using the Modified Ashworth Scale guides management.

💊

Baclofen

Lioresal® · Generic · GABA-B agonist

Adult dose 5 mg PO TDS, titrate by 5 mg every 3–5 days to max 80 mg/day in divided doses

Key warnings Do not stop abruptly (seizures); sedation, weakness; renal impairment reduces clearance

Renal adjustment Reduce dose in eGFR <30 mL/min (accumulation risk)

PBS status ✔ PBS General Benefit

💊

Gabapentin

Neurontin® · Generic · Gabapentinoid

Adult dose 300 mg PO OD/BD, titrate to 300–600 mg TDS (max 3600 mg/day)

Renal adjustment Dose reduce: eGFR 30–59: max 600 mg BD; eGFR 15–29: max 300 mg OD; eGFR <15: 300 mg alternate days

PBS status ✔ PBS General Benefit

💊

Tizanidine

Sirdalud® · α2-adrenergic agonist

Adult dose 2 mg PO at night, titrate by 2 mg every 3–7 days; max 36 mg/day in divided doses TDS

Key warnings Hepatotoxicity — check LFTs at 1, 3, 6 months; potentiated by CYP1A2 inhibitors (ciprofloxacin, fluvoxamine); do not combine with fluvoxamine

PBS status ✔ PBS Authority Required — MS spasticity

For refractory spasticity, specialist interventions include intrathecal baclofen pump (via neurosurgery), botulinum toxin type A (Botox® — PBS authority required for focal spasticity), and intramuscular phenol neurolysis. Referral to MS-specialist physiotherapy and occupational therapy is essential.

Fatigue

MS-related fatigue is the most common symptom (reported in ~75–95% of patients) and is the single greatest predictor of reduced quality of life. It is often described as an overwhelming sense of tiredness disproportionate to activity, worsened by heat (Uhthoff's phenomenon).

💡

Primary care approach to MS fatigue:

First-line: Structured exercise programme (graded aerobic + resistance), energy conservation strategies, occupational therapy assessment, cognitive behavioural therapy (CBT)
Exclude contributing factors: Depression, sleep disorders (OSA common), thyroid dysfunction, anaemia, medications (sedating antispasmodics), deconditioning, nocturia
Pharmacological (second-line, specialist guidance): Amantadine 100 mg PO BD (off-label; PBS not subsidised for fatigue), modafinil (off-label, not PBS-listed for MS fatigue)
Heat management: Cooling garments, air conditioning, avoid hot baths; core body temperature reduction strategies — supported by MS Australia's cooling programme

Bladder Dysfunction

Bladder symptoms affect ~75% of people with MS and include urgency, frequency, nocturia, incontinence (detrusor overactivity), hesitancy, incomplete emptying, and urinary retention (detrusor-sphincter dyssynergia). Initial assessment in primary care includes post-void residual (PVR) volume measurement, MSU to exclude UTI, and bladder diary.

Symptom Pattern	Likely Mechanism	Management
Urgency, frequency, urge incontinence	Detrusor overactivity	Anticholinergics: oxybutynin 2.5–5 mg PO TDS, or solifenacin 5–10 mg PO OD, or mirabegron 50 mg PO OD (β3 agonist, fewer anticholinergic side effects); fluid management; pelvic floor physiotherapy
Hesitancy, poor stream, retention	Detrusor-sphincter dyssynergia / detrusor underactivity	Intermittent self-catheterisation (ISC) — OT/nurse specialist teaching; alpha-blockers (tamsulosin 400 µg PO OD, off-label); avoid anticholinergics
Mixed or refractory symptoms	Combined dysfunction	Urodynamics (referral to urology/neuro-urology); onabotulinumtoxinA 100 units intravesically (PBS authority required); sacral nerve stimulation

⚠️

UTI warning: People with MS are highly susceptible to urinary tract infections, which can trigger pseudorelapses (worsening of existing symptoms due to Uhthoff's effect rather than new inflammatory activity). UTI should be excluded before attributing symptom worsening to a true relapse. Recurrent UTI prophylaxis with trimethoprim 100 mg PO nocte (PBS general benefit) may be considered.

Pain

Chronic pain affects ~50–70% of people with MS and may be neuropathic (central, trigeminal neuralgia), musculoskeletal (secondary to spasticity, immobility), or mixed. Up to one-third describe pain as their worst symptom.

💊

Pregabalin

Lyrica® · Gabapentinoid

Adult dose 75 mg PO BD, titrate to 150–300 mg BD over 1–2 weeks

Renal adjustment eGFR 30–60: max 75–150 mg BD; eGFR 15–30: 25–75 mg OD-BD; eGFR <15: 25 mg OD

PBS status ✔ PBS Authority Required — Neuropathic pain

💊

Amitriptyline

Endep® · Generic · Tricyclic antidepressant

Adult dose 10–25 mg PO at night, titrate to 50–75 mg nightly

Key warnings Anticholinergic effects may worsen bladder dysfunction and cognition; avoid in elderly cardiac disease

PBS status ✔ PBS General Benefit

💊

Carbamazepine

Tegretol® · Sodium channel blocker

Adult dose For trigeminal neuralgia: 100 mg PO BD, titrate to 200–400 mg BD (max 1200 mg/day)

Key warnings Hyponatraemia monitoring; HLA-B*1502 testing in at-risk populations (Asian, Aboriginal and Torres Strait Islander) to prevent SJS/TEN; FBC monitoring for agranulocytosis

PBS status ✔ PBS General Benefit

Mood and Cognitive Impairment

Major depression occurs in up to 50% of people with MS over their lifetime — a rate 2–3 times higher than the general population. Anxiety is equally prevalent. Both are independent of disability level and have profound impacts on treatment adherence, employment, and carer burden. Cognitive impairment (affecting processing speed, memory, and executive function) affects 40–70% of patients.

Screening: PHQ-9 and GAD-7 at every clinical visit (primary care and neurology); Montreal Cognitive Assessment (MoCA) for cognitive concerns
Pharmacological: SSRIs are first-line — sertraline 50–200 mg PO OD (PBS general benefit) or escitalopram 10–20 mg PO OD; avoid fluoxetine if on teriflunomide (CYP interaction)
Non-pharmacological: CBT (evidence-based for MS fatigue, depression, and pain), mindfulness-based stress reduction, exercise programmes, peer support (MS Australia peer support groups)
Neuropsychology referral: Formal cognitive assessment for patients reporting difficulty with work, driving, or daily activities

Monitoring & Safety

Monitoring in MS serves two purposes: (1) tracking disease activity and disability progression to ensure disease-modifying therapy is effective, and (2) screening for treatment-related adverse effects. This is shared between neurology (annual MRI, DMT monitoring) and primary care (vaccination, infection, mental health, comorbidity management).

Disease Activity Monitoring

Parameter	Frequency	Details
MRI brain ± spine	6–12 months on DMT; annually once stable ≥2 years	New/enlarging T2 or gadolinium-enhancing lesions indicate breakthrough disease activity and DMT escalation consideration
EDSS (Expanded Disability Status Scale)	6-monthly neurology review	Standardised disability scoring; sustained progression ≥1.0 point (if EDSS ≤5.5) or ≥0.5 point (if EDSS ≥5.5) over ≥3–6 months indicates disease progression
Relapse documentation	At each visit	Date, symptoms, duration, residual deficits, corticosteroid use. Annualised relapse rate (ARR) — primary outcome measure
No Evidence of Disease Activity (NEDA-3)	Annually	NEDA-3 = no relapses + no MRI activity + no disability progression. Aims to redefine treatment targets

DMT-Specific Safety Monitoring

DMT	Key Monitoring	Primary Care Role
Interferon-β / Glatiramer	FBC, LFTs, TFTs (interferon only)	Monitor for depression (interferon); injection site reactions
Dimethyl fumarate	FBC with absolute lymphocyte count (ALC) — hold if ALC <0.5 × 10⁹/L; LFTs	Report infections; GI side effects management; flushing (take with food)
Teriflunomide	LFTs monthly for 6 months then 6-monthly; FBC; blood pressure; pregnancy test (mandatory)	Contraception counselling — teratogenic (requires active elimination with cholestyramine if pregnancy planned)
Fingolimod / Siponimod	First-dose 6-hour cardiac monitoring (HR, BP, ECG); FBC, LFTs, ophthalmology (macular oedema) at 3–4 months; dermatological skin cancer screening	Bradyarrhythmia awareness; infection reporting; avoidance of live vaccines
Natalizumab	JC virus antibody status every 6 months; MRI every 6–12 months (PML surveillance); LFTs	Report new neurological symptoms immediately (PML: subacute cognitive decline, seizures, focal deficits); coordinate with neurology for extended interval dosing
Ocrelizumab	Immunoglobulin levels (IgG) annually; hepatitis B screening pre-treatment; FBC pre-infusion	Infection vigilance (especially respiratory); hypogammaglobulinaemia management; vaccination updates
Cladribine	FBC with differential lymphocytes (critical — lymphopenia grading); herpes prophylaxis if Grade 3–4 lymphopenia; LFTs	Infection reporting; vaccination timing (avoid live vaccines 4–6 weeks before and during lymphopenia)
Alemtuzumab	Monthly FBC, renal, LFTs, TFTs, urinalysis for 48 months post-last infusion (risk of secondary autoimmune conditions: thyroid, ITP, anti-GBM disease)	Monitor for autoimmune thyroid disease, ITP (bruising, petechiae), Goodpasture's (haematuria, dyspnoea); annual cancer screening

Vaccination

💉

Critical vaccination guidance:

Before starting immunosuppressive DMTs: Complete all scheduled vaccinations at least 4–6 weeks prior to initiation. This includes influenza (annually), pneumococcal (Prevenar 13 then Pneumovax 23), shingles (Shingrix — non-live, preferred), hepatitis B, HPV (if not previously completed), COVID-19 boosters.
Live vaccines contraindicated during treatment with: fingolimod, siponimod, natalizumab, ocrelizumab, alemtuzumab, cladribine, and during significant lymphopenia on dimethyl fumarate or teriflunomide. Contraindicated live vaccines include: MMR, varicella (if non-immune — use Zostavax with caution, Shingrix preferred), yellow fever, oral typhoid, BCG, oral polio, live attenuated influenza (FluMist).
Shingrix (recombinant, non-live) is preferred over Zostavax for all patients with MS on immunosuppressive therapy. Available PBS-funded for adults ≥65 years (general population) or ≥18 years if immunocompromised.
Household contacts should be fully vaccinated, including annual influenza vaccine.
COVID-19 vaccination: All people with MS should receive COVID-19 vaccines including boosters. Timing relative to DMT infusions may require coordination (e.g., ocrelizumab — vaccinate ≥12 weeks post-infusion and ≥4 weeks before next infusion for optimal immune response).

Infection Risk

People with MS on immunosuppressive DMTs are at increased risk of infection. Common infections include urinary tract infections (see Bladder section), respiratory infections, herpes zoster, and (rarely) opportunistic infections.

Progressive multifocal leukoencephalopathy (PML): JC virus reactivation — highest risk with natalizumab (JCV antibody positive + prior immunosuppression + >2 years treatment = ~1/75 risk). Presents subacutely with cognitive changes, speech disturbance, motor deficits. MRI shows unilateral/asymmetric T2 lesions, often parieto-occipital, without mass effect. Requires urgent MRI + CSF JCV PCR.
Herpes infections: Increased with fingolimod, siponimod, cladribine, alemtuzumab. Consider valaciclovir prophylaxis in patients with recurrent herpes.
Hepatitis B reactivation: Screen all patients before ocrelizumab, alemtuzumab; treat/reactivate prophylaxis if HBsAg positive or anti-HBc positive.
Hypogammaglobulinaemia: Monitor IgG levels with ocrelizumab and cladribine; refer to immunology if recurrent infections and IgG <4 g/L; IVIg replacement may be required.

Pregnancy and Contraception

MS predominantly affects women of childbearing age. Pregnancy planning is essential, and most disease-modifying therapies require specific washout periods or are contraindicated in pregnancy.

🤰

Pregnancy and DMT — key principles:

Teriflunomide: Teratogenic — absolutely contraindicated in pregnancy. Active elimination with cholestyramine 8 g TDS for 11 days required before conception. Must verify plasma level <0.02 mg/L before attempting pregnancy. Two forms of contraception required during treatment.
Fingolimod: Teratogenic — washout period ≥2 months before conception. Risk of severe rebound relapse on cessation. Requires careful neurology planning.
Cladribine: Contraindicated in pregnancy. Wait ≥6 months after last course before conception.
Alemtuzumab: Contraindicated in pregnancy. Wait ≥4 months after last infusion. Effective contraception for 4 months post-treatment.
Natalizumab: May be continued until conception or into early pregnancy under specialist supervision if high disease activity — risk of rebound on cessation. Decision requires neurology involvement.
Ocrelizumab: Wait ≥6 months after last infusion before conception. B-cell depletion may persist for 12+ months.
Interferon-β and glatiramer: Generally discontinued upon confirmed pregnancy. Teratogenicity data are reassuring but precautionary approach is standard.
Relapse risk: Low during pregnancy (especially 3rd trimester due to immune tolerance), increased in the first 3–6 months postpartum. Breastfeeding may be protective (recent evidence supports DMT continuation in select patients).

Contraception Counselling

Effective contraception is mandatory during treatment with teriflunomide, fingolimod, siponimod, cladribine, and alemtuzumab
Long-acting reversible contraception (LARC — IUD, implant) is recommended due to high efficacy independent of adherence
Enzyme-inducing anticonvulsants (carbamazepine, phenytoin — used for MS-related pain/spasticity) reduce efficacy of hormonal contraception; use copper IUD or higher-dose combined methods
Contraception and pregnancy planning should be discussed at every visit from diagnosis onwards

Special Populations

🤰

Pregnancy

MS does not affect fertility, pregnancy outcomes, or risk of congenital abnormality

Relapse rate decreases by ~70% during pregnancy (especially trimester 3)

Postpartum relapse risk is modestly increased (first 3–6 months) but does not affect long-term disability trajectory

For acute relapse in pregnancy: IV methylprednisolone 1 g daily for 3–5 days (second/third trimester preferred; avoid first trimester if possible); plasmapheresis as second-line

Teriflunomide, fingolimod: absolutely contraindicated. Natalizumab: may be continued until conception under neurology supervision. Ocrelizumab: plan ≥6 months pre-conception. Interferon-β/glatiramer: discontinue at positive pregnancy test.

Coordinate multidisciplinary care: neurology, obstetrics, neonatology. Breastfeeding is encouraged — emerging evidence supports immunoprotective benefits for mother.

👶

Paediatric MS

Paediatric-onset MS accounts for ~3–5% of all MS; mean age of onset ~13 years (can occur from age 2 years)

Higher relapse rate than adult-onset MS but may have better recovery initially

Cognitive impairment is more prevalent and has greater educational impact than in adults

Must exclude acute disseminated encephalomyelitis (ADEM), MOGAD, and NMOSD — these are more common in children

First-line DMTs: fingolimod (PBS-listed for paediatric MS ≥10 years); interferon-β and glatiramer used off-label in younger children. High-efficacy DMTs (natalizumab, ocrelizumab) for aggressive disease.

Specialist paediatric neurology management required. Transition to adult MS services at 16–18 years with planned handover. Educational support through individualised education plans.

👴

Elderly (≥60 years)

MS activity (relapses, new MRI lesions) typically decreases with age; progressive pathology predominates

DMT efficacy decreases after age ~45–50 years; benefit-risk ratio of continued immunosuppression should be reassessed regularly

Increased risk of DMT adverse effects (infections, malignancy); consider de-escalation or cessation in patients ≥60 with stable disease

Comorbidity management becomes paramount: cardiovascular disease, diabetes, osteoporosis, falls prevention

Polypharmacy risk — review all medications; reduce anticholinergic burden (cognitive impact); gabapentin/pregabalin dose reduction for renal function; consider baclofen clearance

Geriatric medicine co-management for complex multimorbidity. Falls risk assessment using Physiological Profile Assessment or Timed Up and Go. Bone health — vitamin D + calcium supplementation; DEXA if prolonged corticosteroid use.

🫘

Renal Impairment

Most DMTs do not require renal dose adjustment (interferon-β, glatiramer, natalizumab, ocrelizumab)

Gadolinium-based MRI contrast agents: use macrocyclic agents only in eGFR <30 mL/min (risk of nephrogenic systemic fibrosis with linear agents); avoid if eGFR <15 unless essential

Baclofen: dose reduce in eGFR <30 (accumulation → confusion, sedation, respiratory depression). Gabapentin/pregabalin: mandatory dose reduction per eGFR. Dimethyl fumarate: caution but no specific adjustment. Dalfampridine (4-aminopyridine): contraindicated in eGFR <50 (seizure risk).

Renal impairment may worsen with prolonged high-dose corticosteroid use (fluid overload, hypertension). Monitor electrolytes during methylprednisolone courses.

🫁

Hepatic Impairment

Teriflunomide: contraindicated in severe hepatic impairment (Child-Pugh C); caution in moderate impairment

Tizanidine: extensively hepatically metabolised — contraindicated in severe impairment; significant hepatotoxicity risk even in normal hepatic function

Interferon-β: may cause transaminitis — monitor LFTs; discontinue if ALT >5× ULN

Fingolimod: no specific contraindication but caution in severe hepatic impairment. Dimethyl fumarate: avoid in severe liver disease. Ocrelizumab: no hepatic dose adjustment required.

Hepatitis B reactivation screening mandatory before ocrelizumab and alemtuzumab. Corticosteroid use in patients with hepatic steatosis may worsen glycaemic control.

🛡️

Immunocompromised

All immunosuppressive DMTs increase infection risk to varying degrees — lowest with glatiramer and interferon-β, highest with alemtuzumab and prolonged natalizumab

Screen for latent TB (quantiferon gold) before starting ocrelizumab, alemtuzumab — especially in immigrants from high-prevalence countries

Hepatitis B and C screening before starting any DMT

HIV screening should be performed in all patients with suspected MS

Avoid combining two immunosuppressive therapies. If switching DMTs, account for overlapping immune suppression (e.g., lymphocyte recovery time after fingolimod before starting ocrelizumab).

Malignancy screening per national guidelines. Lymphoma risk may be modestly increased with some DMTs. Regular dermatological review for non-melanoma skin cancer (fingolimod, siponimod).

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Multiple sclerosis in Aboriginal and Torres Strait Islander Australians is an under-researched area. Limited epidemiological data suggest MS prevalence is lower in Indigenous Australians compared to non-Indigenous Australians, though diagnostic delay and under-ascertainment likely contribute to this apparent difference. When MS does occur, the burden of disease is compounded by comorbidities, reduced access to specialist services, and socioeconomic disadvantage.

⚠️

Key concerns for Aboriginal and Torres Strait Islander peoples with MS: Diagnostic delay is significant — the median time from symptom onset to diagnosis may be substantially longer due to geographic barriers, reduced access to MRI, limited specialist neurology presence in rural and remote areas, and culturally inappropriate service delivery models that do not address health literacy, communication styles, or cultural obligations.

Geographic and specialist access

Most MS neurologists are based in metropolitan centres. Aboriginal and Torres Strait Islander peoples in rural and remote communities (particularly in the Northern Territory, Western Australia, Far North Queensland) may face delays of weeks to months for specialist assessment. Telehealth through the Royal Flying Doctor Service (RFDS) and state-based telehealth networks should be actively facilitated. MRI access is limited outside major regional centres — MBS-funded portable MRI units and outreach programmes are expanding but remain insufficient.

Cultural safety in care delivery

MS diagnosis and management require culturally safe, trauma-informed approaches. Concepts of neurological disability may carry significant cultural meaning and stigma. Aboriginal Health Workers and Aboriginal Liaison Officers should be involved in all aspects of MS care — from initial consultation to DMT counselling and symptom management. Acknowledge kinship obligations and sorry business when scheduling appointments. Use plain language and visual aids; avoid medical jargon.

DMT adherence and monitoring

Regular monitoring (blood tests, MRI, specialist appointments) for DMTs can be extremely challenging in remote settings. Self-injectable DMTs (interferon-β, glatiramer) may be preferred where infusion services are unavailable, though community-controlled health services may facilitate infusion visits through patient-assisted travel schemes (PATS). Long-acting DMTs (cladribine — oral, limited dosing days) may offer logistical advantages.

Comorbidity burden

Aboriginal and Torres Strait Islander Australians have higher rates of diabetes, cardiovascular disease, chronic kidney disease, and rheumatic heart disease. These comorbidities interact with MS management — renal impairment affects gabapentinoid and baclofen dosing; diabetes accelerates MS disability; immunosuppressive DMTs require infection vigilance in communities with high rates of skin infections and respiratory disease. Integrated chronic disease management within Aboriginal Community Controlled Health Services (ACCHS) is essential.

Vaccination and infection prevention

Aboriginal and Torres Strait Islander peoples have higher rates of hepatitis B carriage, rheumatic fever requiring long-term penicillin, and respiratory infections. Pre-DMT vaccination catch-up programmes should be coordinated through ACCHS. Shingrix (non-live) is preferred over Zostavax. Ensure annual influenza and pneumococcal vaccination. Culturally appropriate education about immunosuppression risks from DMTs is vital.

Mental health and social determinants

Depression, anxiety, and substance use disorders are more prevalent and contribute to poor MS outcomes. Social determinants — housing insecurity, food insecurity, family disruption, intergenerational trauma — significantly impact disease management. Culturally responsive mental health services, yarning circles, and connection to Country should be incorporated into holistic MS care plans. Referral to Indigenous-specific mental health services (e.g., Yarning About Mental Health programmes) is recommended.

All health professionals managing MS in Aboriginal and Torres Strait Islander patients should complete cultural safety training and engage with local Aboriginal Community Controlled Health Organisations (ACCHOs) to ensure integrated, culturally responsive care pathways.

📚 References

1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi:10.1016/S1474-4422(17)30470-2
2. Australian Institute of Health and Welfare (AIHW). Multiple sclerosis in Australia. Cat. no. ACM 35. Canberra: AIHW; 2024.
3. MS Australia. MS Prevalence in Australia — Updated Estimates. Sydney: MS Australia; 2023. Available at: msra.org.au.
4. Filippini G, Del Giovane C, Clerico M, et al. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017;4(4):CD012200. doi:10.1002/14651858.CD012200.pub2
5. Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later long-term outcomes in multiple sclerosis: the LIFT study. JAMA Neurol. 2019;76(2):178-187.
6. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.
7. Palace J, Lin DY, Zeng D, et al. Outcome prediction models in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2019;85(5):653-665.
8. Langer-Gould A, Moses HH, Murray TJ. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2020;77(12):1531-1538.
9. Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: Association of British Neurologists guidelines. Pract Neurol. 2019;19(2):106-114.
10. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788.
11. Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;(9):CD011381.
12. Australian Bureau of Statistics (ABS). Estimates of Aboriginal and Torres Strait Islander Australians. Canberra: ABS; 2024. Cat. no. 3238.0.55.001.
13. Fragoso YD, Ferreira ML, et al. Vaccination and the risk of multiple sclerosis relapse: a meta-analysis. Multiple Sclerosis and Related Disorders. 2023;71:104535.
14. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373(15):1418-1429.
15. National Health and Medical Research Council (NHMRC). National Statement on Ethical Conduct in Human Research. Canberra: NHMRC; 2023 (updated). Relevant to research inclusion of Aboriginal and Torres Strait Islander peoples in MS clinical trials.